Back to search results

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Abroad (travel likely)RecruitingPHASE2

Conditions

Fallopian Tube Carcinosarcoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Serous Adenocarcinoma · Ovarian Carcinosarcoma · Ovarian Clear Cell Adenocarcinoma · Ovarian Endometrioid Adenocarcinoma · Ovarian Serous Adenocarcinoma · Primary Peritoneal Carcinosarcoma · Primary Peritoneal Clear Cell Adenocarcinoma · Primary Peritoneal Endometrioid Adenocarcinoma · Primary Peritoneal Serous Adenocarcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads

  • Emese Zsiros

    Principal Investigator

    Roswell Park Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)